Medical Journals

Angiogenic Cells Can Be Rapidly Mobilized and Efficiently Harvested from the Blood Following Treatment with Amd3100.

Authors:
  • Shepherd Rebecca M
  • Capoccia Benjamin J
  • Devine Steven M
  • Dipersio John
  • Trinkaus Kathryn M
  • Ingram David
  • Link Daniel C

From: Division of Oncology, Department of Medicine, 660 S Euclid Ave, Campus Box 8007, Saint Louis, MO 63110, USA.

Blood

  • Publish Date: Dec 2006
  • ISSN: 0006-4971
  • Volume: 108
  • Issue: 12
  • Pages: 3662-7
  • Medium: Print
  • Language: English
  • Citation (JAMA): Shepherd Rebecca M, Capoccia Benjamin J, Devine Steven M, et al. Angiogenic Cells Can Be Rapidly Mobilized and Efficiently Harvested from the Blood Following Treatment with Amd3100.. Blood Dec 2006;108:3662-7

Abstract

Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold +/- 4.4-fold and 8.8-fold +/- 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold +/- 3.3-fold and 21.8-fold +/- 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF-mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.

Mesh Headings (Keywords): Animals, Anti-HIV Agents, Blood Donors, Cell Proliferation, Cryopreservation, Endothelial Cells, Female, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Humans, Injections, Subcutaneous, Leukapheresis, Male, Mice, Mice, Inbred NOD, Mice, SCID, Neovascularization, Physiologic, Stem Cell Transplantation, Stem Cells


Check for Full Text / PubMed Unique Identifier (PMID): 16912220


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.